MedTrace Logo

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

NCT03672292 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.

Conditions

  • Invasive Pulmonary Aspergillosis

Interventions

DRUG

SCY-078

Oral tablets of SCY-078

DRUG

Voriconazole

Voriconazole IV vials or oral tablets

OTHER

Oral Placebo Tablets

Oral Placebo Tablets matching SCY-078

Sponsors & Collaborators

  • Scynexis, Inc.

    lead INDUSTRY

Principal Investigators

  • David Angulo, MD · Scynexis, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-22
Primary Completion
2023-03-27
Completion
2023-03-27
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Germany
  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03672292 on ClinicalTrials.gov